|
|
|
|
|
Big Deals
|
|
|
| By
The Pharm Exec staff
|
|
|
|
Many say licensing is the new R&D. We've rounded up the unions to watch from the third quarter of 2007.
|
|
|
|
Brand of the Year 2008
|
|
|
| By
Walter Armstrong
|
|
|
|
With Chantix, Pfizer combined inspired drug design with innovative customer-focused marketing to make the first real medical assault on nicotine addiction.
|
|
|
|
Basic Training: Trends in Learning & Development Departments
|
|
|
| By
Rayna Herman
,
Laura Ramos
|
|
|
|
Can pharma take its talent—and its earning potential—to the next level with employee education?
|
|
|
|
Fight Resistance
|
|
|
| By
Joanna Breitstein
|
|
|
|
US officials think they can control MRSA and other "superbugs," but dangerous bacteria know no boundaries. What does the world do when its drugs stop working?
|
|
|
|
|
|
|
|
|
Funding Follies at FDA
|
|
|
| By
Jill Wechsler
|
|
|
|
Congress blocked DTC user fees, Reagan-Udall, field force reforms while slightly bumping FDA's budget
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Calling All Leaders
|
|
|
| By
Patrick Clinton
|
|
|
|
New from Pharm Exec: a blog, expanded tech and deals coverage, and a new awards program for emerging pharma leaders
|
|
|
|